Loading stock data…
Molecular Partners AG (MOLN)
$3.96+0.16 (+4.21%)
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Molecular Partners AG in the Healthcare sector is trading at $3.96 with a market capitalization of $143M. Wall Street consensus targets $10.81 (5 analysts), implying a +173.1% move over the next 12 months. The stock is currently 26% below its 52-week high of $5.36, remaining 5.0% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +173.1% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$13.44M↓ | -$12.67M↓ | -$11.93M↑ | -$14.70M↑ | -$16.14M |
| Net Income | -$13.14M↓ | -$12.65M↓ | -$11.84M↑ | -$20.40M↓ | -$16.77M |
Peer Comparison
JNJUNHPFE
Fundamentals
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinic...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$143.29M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-84.77%
Volume
Today's trading volume
9,077
Recent News
Eckert & Ziegler SE (XTER:EUZ) Q1 2026 Earnings Call Highlights: Strong Medical Division ...
Eckert & Ziegler SE (XTER:EUZ) reports a 7% sales increase, driven by a robust medical division, while facing currency impacts and revenue declines in the isotope segment.
3 European Penny Stocks With Market Caps Under €600M
The European stock market has recently experienced a positive shift, with the STOXX Europe 600 Index climbing by 3.92% amid hopes for a resolution to Middle East tensions. As investors navigate these fluctuating conditions, penny stocks—often smaller or newer companies—remain an intriguing area of exploration. Despite being an older term, penny stocks can present unique opportunities when they possess strong financials and growth potential, offering investors the chance to uncover hidden...
Molecular Partners Highlights Favorable MP0712 DLL3 Radiotherapeutic Imaging, U.S. Phase I/II Ready
Molecular Partners (NASDAQ:MOLN) hosted a webcast to discuss clinical imaging and dosimetry data for MP0712, its DLL3-targeting radiotherapeutic program, following a presentation at the Theranostics World Conference in South Africa. Company executives said the data came from a named patient access p
Molecular Partners AG (VTX:MOLN) is definitely on the radar of hedge funds investors who own 50% of the company
Key Insights Given the large stake in the stock by institutions, Molecular Partners' stock price might be vulnerable to...
Stocks Look Set to Open Trading Session Marginally Lower Wednesday as Investors Look Ahead to Nvidia Earnings
US stocks look set to open flat in Wednesday's trading session as investors await Nvidia's Q2 result